Wird geladen...
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032
The BRAF(V600E) mutation, which approaches 50% in human melanomas, constitutively activates pERK and contributes to disease progression. The BRAF(V600E) inhibitor, Vemurafenib (PLX4032), shows promising clinical responses, but resistance to PLX4032 usually develops within a year. Transgenic mouse mo...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3988244/ https://ncbi.nlm.nih.gov/pubmed/24460976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12220 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|